AMG 133 Combines GIPR Antagonism With GLP-1 Agonism in a Single Monthly Injection for Obesity

A once-monthly antibody-peptide conjugate that blocks GIPR while activating GLP-1 receptors achieved sustained weight loss in preclinical obesity models and is now in Phase III trials — a potential step-change in dosing convenience for obesity pharmacotherapy.

AMG 133, also known as maridebart cafraglutide, is a bispecific molecule developed by Amgen that covalently links a synthetic GLP-1 receptor agonist peptide to an anti-GIPR (glucose-dependent insulinotropic polypeptide receptor) antagonist antibody. The rationale: GLP-1R agonism suppresses appetite and improves glycemic control, while GIPR antagonism may enhance weight loss through complementary metabolic pathways. By conjugating the peptide to an IgG backbone, the construct dramatically extends the circulating half-life of the GLP-1 peptide component.

Key Findings

In a paper published in the Journal of Medicinal Chemistry, Wu et al. describe the medicinal chemistry campaign that led to AMG 133's discovery.¹

Preclinical efficacy:

• In diet-induced obese (DIO) mice, once-weekly dosing of the anti-GIPR-Ab/GLP-1 conjugate produced dose-dependent body weight reductions superior to GLP-1 peptide alone.
• In obese cynomolgus monkeys, the conjugate achieved sustained weight loss with once-weekly administration and improved metabolic parameters including glucose tolerance.
• The antibody scaffold conferred markedly prolonged systemic exposure of the structurally intact GLP-1 peptide compared to unconjugated peptide.

Molecular design:

• A series of hybrid molecules was generated by conjugating synthetic GLP-1 peptides to IgG-based anti-GIPR antibodies at defined sites.
• Optimization focused on peptide potency, conjugation chemistry, and pharmacokinetic stability.
• The final AMG 133 construct demonstrated a pharmacokinetic profile consistent with monthly dosing in humans.

Why This Matters

The obesity therapeutics landscape is dominated by weekly injectable GLP-1RAs (semaglutide, tirzepatide). AMG 133 introduces two differentiators: a novel mechanism (GIPR antagonism rather than the GIPR agonism used by tirzepatide) and a potentially monthly dosing schedule. If Phase III data confirm the preclinical promise, this could meaningfully improve patient adherence by reducing injection frequency from 52 to 12 times per year.

The GIPR antagonism vs. agonism debate remains unresolved. Tirzepatide achieves impressive weight loss via dual GIPR/GLP-1R agonism, while AMG 133 bets on the opposite GIPR approach. Head-to-head mechanistic comparisons will be needed to determine which strategy delivers superior long-term outcomes.

Clinical implication: Prescribers should watch for Phase III readouts of AMG 133 (expected 2026–2027), as a monthly injectable with dual-mechanism weight loss could become a compelling alternative to current weekly GLP-1 receptor agonists for patients who struggle with injection frequency.

---

¹ Wu B, Falsey JR, Netirojjanakul C, et al. Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. J Med Chem. 2026. doi:10.1021/acs.jmedchem.6c00032